PARIS, June 2 (Reuters) - French pharma group Sanofi
has agreed to buy US-based Blueprint Medicines
Corporation ( BPMC ), a biopharmaceutical company specializing
in systemic mastocytosis, a rare immunological disease, the
companies said on Monday.
Under the terms of the acquisition, Sanofi will pay $129.00
per share in cash, representing an equity value of approximately
$9.1 billion.